Report cover image

2025 North America 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report

Publisher Wharry Sharpe Research
Published Sep 01, 2025
Length 51 Pages
SKU # WSR20382171

Description

The 2025 North America 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)

The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.

Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)

The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,

The four largest companies actively involved in the 23-valent Pneumococcal Vaccine Market in North America are Pfizer Inc., Merck & Co., Inc., Sanofi Pasteur, and GlaxoSmithKline plc (GSK). Pfizer leads with its Prevnar line, including the recently FDA-approved PREVNAR 20 vaccine, leveraging strong R&D and extensive distribution networks. Merck specializes in Pneumovax 23, a widely used polysaccharide vaccine for older adults. Sanofi Pasteur and GSK contribute with ongoing vaccine developments and strategic expansions aimed at pediatric and adult immunization markets, emphasizing equitable vaccine access and innovation.

These companies dominate a market projected to grow due to rising pneumococcal disease incidence and vaccination efforts. North America holds a significant revenue share in this market, with the pneumococcal conjugate vaccine segment showing the fastest growth. Their competitive strategies include advancing vaccine formulations, regulatory approvals, partnerships, and scaling manufacturing to meet healthcare demands across the region.

Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.

This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.

Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.

Table of Contents

51 Pages
A. Definitions
A1. Market Definition
A2. Market Segmentation
A3. Industry Opportunities-Industry1
A4. Industry Opportunities-Industry2
A5. Industry Opportunities-Industry3
B. Total Addressable Market (TAM)
B1. TAM-Player 1/4
B2. TAM-Player 2/4
B3. TAM-Player 3/4
B4. TAM-Player 4/4
C. Serviceable Addressable Market (SAM)
C1. SAM-Player 1/4
C2. SAM-Player 2/4
C3. SAM-Player 3/4
C4. SAM-Player 4/4
D. Serviceable Obtainable Market (SOM)
D1. SOM-Player 1/4
D2. SOM-Player 2/4
D3. SOM-Player 3/4
D4. SOM-Player 4/4
E. Appendix

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us